When was Vividion Therapeutics founded?

Vividion Therapeutics was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Vividion Therapeutics located?

Vividion Therapeutics is headquartered in Oceanside, United States. It is registered at San Diego,California.

How many employees does Vividion Therapeutics have?

As of Aug 31, 2026, the latest employee count at Vividion Therapeutics is 268.

Is Vividion Therapeutics a funded company?

Vividion Therapeutics is a funded company, having raised a total of $271M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 31, 2016.

How much is Vividion Therapeutics worth?

The last known valuation of Vividion Therapeutics was $***** as of Aug 19, 2021.

When was the latest funding round of Vividion Therapeutics?

Vividion Therapeutics' latest funding was a $***** Series C round on Feb 18, 2021, with participation from 9 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $4.09B in funding in 2026 to date.

Where does Vividion Therapeutics rank among its competitors?

Vividion Therapeutics ranks 170th amongst 3678 active competitors, of which 1225 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Vividion Therapeutics?

Vividion Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Vividion Therapeutics - 2026 Company Profile, Funding & Competitors

Q: Is Vividion Therapeutics an acquired company?

Vividion Therapeutics got acquired by Bayer on Aug 05, 2021.

Company Details

Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers. The company is dedicated to transforming patient care through small molecule therapeutics, addressing unmet needs in cancers and immunological diseases. Their innovative drug discovery engine leverages a unique chemoproteomics platform to identify and pursue novel strategies for previously inaccessible disease-causing proteins. This approach enables the development of precision therapeutics with the potential to modulate protein targets that have eluded conventional methods. Committed to scientific innovation and patient impact, they strive to forge life-changing connections between therapeutics and undrugged drivers of disease, expanding the reach of small molecule therapies and improving outcomes for patients with devastating illnesses. Their comprehensive approach spans the full arc of drug development, from screening via their drug discovery platform through therapeutic development in the clinic.

Website: vividion.com
Social
Email ID: *****@vividion.com
Registered Address: San Diego,California

Key Metrics

Founded Year

2016

Location

Oceanside, United States

Stage

Acquired

Total Funding

$271M in 4 rounds

Latest Funding Round

Series C, Feb 18, 2021, $*****

Last Known Valuation

$***** as on Aug 19, 2021

Investors

Arch Venture Partners & 22 more

Ranked

170^th among 3678 active competitors

Employee Count

268 as on Aug 31, 2026

Investment & Acquisitions

Tavros

Similar Companies

Jazz Pharmaceuticals & 3423 more

Exit Details

Acquired by Bayer (Aug 05, 2021)

View Vividion Therapeutics' full profile

Vividion Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VIVIDION CIN: 464373293 , United States, Active	Dec 31, 1999	-	254 (As on Dec 31, 2024)	-

Vividion Therapeutics got acquired by Bayer on Aug 05, 2021 at an acquisition amount of $*****.

Click here to take a look at Vividion Therapeutics's acquisition in detail

Vividion Therapeutics has raised a total funding of $271M over 4 rounds. Its first funding round was on Mar 31, 2016. Its latest funding round was a Series C round on Feb 18, 2021 for $*****. 9 investors participated in its latest round. Vividion Therapeutics has 23 institutional investors.

Here is the list of recent funding rounds of Vividion Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 18, 2021	2800969	Series C	9060366	4608828	9358109	3849323
Apr 24, 2019	6050893	Series B	5293920	9989905	4255377	Casdin Capital & 10 more
Jan 03, 2017	5402668	Series A	5995562	2583129	Arch Venture Partners & 1 more	7124415

Access funding benchmarks and valuations. Sign up today!

View details of Vividion Therapeutics's funding rounds and investors

Vividion Therapeutics' employee count trend

Vividion Therapeutics has 268 employees as of Aug 26. Here is Vividion Therapeutics's employee count trend over the years:

Employee count trend for Vividion Therapeutics

Uncover Vividion Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vividion Therapeutics include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Vividion Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
170th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	BVF Partners, Boxer Capital & 21 others	61/100